Total amount: € 0,00
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236
Online ISSN 1827-1669
Frizziero L., Focherini M. C., Valentini M., Reta M., Rocchi P.
Background. To assess the long term safety and therapeutic action of lornoxicam, a new non steroidal anti-inflammatory agent, in rheumatoid arthritis.
Methods. Open trial was carried out on different dosage schedules of lornoxicam (4 or 8 mg bid and 4mg tid) administered for six to twelve months. Patients of both sexes were enrolled, with classical or definite rheumatoid arthritis according to the A.R.A. criteria.
Results. Thirty-four patients (28 F, 6 M) were admitted, mean age (± SD) 53.9±14.2 years, mean duration of illness 9.2±10.7 years. Lornoxicam 8-16 mg/day showed good safety and therapeutic activity in long term treatment. Clinical improvement was limited, but progression of the disease was controlled. No adverse events were complained.
Conclusions. Lornoxicam presented a worth-while therapeutic action and a good tolerability in rheumatoid arthritis long term treatment.